Source comparison
CJC-1295 Results After 2 Weeks: [Peptide Type] Comparison
| Peptide | Mechanism | Half-Life | Week 2 Observations | Tissue-Level Timeline | Professional Assessment ||—|—|—|—|—|| CJC-1295 (DAC) | GHRH receptor agonist. Amplifies endogenous pulsatile GH secretion | 6–8 days | Elevated serum GH (2–10× baseline), IGF-1 r
This comparison does not assign a generated winner or score.
- | Peptide | Mechanism | Half-Life | Week 2 Observations | Tissue-Level Timeline | Professional Assessment ||—|—|—|—|—|| CJC-1295 (DAC) | GHRH receptor agonist. Amplifies endogenous pulsatile GH secretion | 6–8 days | Elevated serum GH (2–10× baseline), IGF-1 rise (1.5–2× baseline), improved sleep architecture, HRV increase 5–12% | 8–12 weeks for lean mass gain, fat loss, skin quality improvement | Best for protocols requiring sustained, physiological GH elevation without daily dosing. Mimics natural secretion rhythm || CJC-1295 (No DAC) | GHRH receptor agonist. Shorter half-life, more frequent dosing | 30 minutes (requires multiple daily doses) | Similar GH pulse amplitude but requires 2–3× daily administration to match DAC version | 8–12 weeks (same tissue timeline as DAC version) | Preferred for protocols requiring precise control over GH pulse timing or shorter washout periods || Ipamorelin | Ghrelin receptor agonist. Stimulates GH release via different pathway | 2 hours | Moderate